China Universal Asset Management Co. Ltd. Increases Stock Position in MaxCyte, Inc. (NASDAQ:MXCT)

China Universal Asset Management Co. Ltd. grew its stake in MaxCyte, Inc. (NASDAQ:MXCT) by 64.6% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 20,212 shares of the company’s stock after acquiring an additional 7,930 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in MaxCyte were worth $79,000 as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in MXCT. Swedbank AB acquired a new position in MaxCyte during the first quarter worth $6,704,000. Chevy Chase Trust Holdings LLC lifted its stake in MaxCyte by 2,182.6% during the 1st quarter. Chevy Chase Trust Holdings LLC now owns 1,296,397 shares of the company’s stock worth $5,432,000 after acquiring an additional 1,239,602 shares in the last quarter. Marshall Wace LLP acquired a new position in MaxCyte in the 2nd quarter valued at about $1,959,000. River Global Investors LLP increased its stake in MaxCyte by 24.4% during the first quarter. River Global Investors LLP now owns 1,888,642 shares of the company’s stock worth $7,973,000 after purchasing an additional 369,996 shares during the period. Finally, Dimensional Fund Advisors LP lifted its position in shares of MaxCyte by 13.6% during the second quarter. Dimensional Fund Advisors LP now owns 1,010,292 shares of the company’s stock worth $3,961,000 after purchasing an additional 121,090 shares in the last quarter. 68.81% of the stock is currently owned by institutional investors and hedge funds.

MaxCyte Stock Performance

Shares of MXCT stock opened at $3.58 on Friday. MaxCyte, Inc. has a fifty-two week low of $2.92 and a fifty-two week high of $5.55. The company has a 50 day moving average price of $3.91 and a 200 day moving average price of $4.18. The stock has a market capitalization of $376.51 million, a P/E ratio of -10.53 and a beta of 1.39.

MaxCyte (NASDAQ:MXCT) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.05. The business had revenue of $10.43 million during the quarter, compared to the consensus estimate of $8.20 million. MaxCyte had a negative net margin of 77.97% and a negative return on equity of 15.52%. During the same quarter in the previous year, the firm posted ($0.10) earnings per share. On average, research analysts forecast that MaxCyte, Inc. will post -0.44 EPS for the current fiscal year.

Insider Transactions at MaxCyte

In related news, Director Stanley C. Erck sold 21,607 shares of MaxCyte stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $3.71, for a total value of $80,161.97. Following the completion of the transaction, the director now owns 269,118 shares in the company, valued at $998,427.78. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other MaxCyte news, Director Stanley C. Erck sold 29,767 shares of the firm’s stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $3.97, for a total value of $118,174.99. Following the sale, the director now directly owns 269,118 shares in the company, valued at $1,068,398.46. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Stanley C. Erck sold 21,607 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $3.71, for a total value of $80,161.97. Following the transaction, the director now directly owns 269,118 shares of the company’s stock, valued at approximately $998,427.78. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 60,374 shares of company stock valued at $233,797. 3.00% of the stock is currently owned by corporate insiders.

MaxCyte Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.